Encouraging response to amifostine, pentoxifylline, ciprofloxacin, dexamethasone (A-PCD) ± topotecan in patients with myelodysplastic syndromes (MDS).

被引：0
|
作者：
Raza, A
Dar, S
Borok, R
Lisak, L
Andrews, C
Ekbal, M
Mazzoran, L
Zorat, F
Rifkin, S
Robin, E
Gregory, S
Venugopal, P
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Rush Canc Inst, Chicago, IL 60612 USA
[2] NW Community Hosp, Arlington Hts, IL USA
[3] Ingalls Mem Hosp, Harvey, IL USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1365
引用
收藏
页码：305A / 305A
页数：1
相关论文
共 50 条
  • [31] Impact Of The Achievement Of a Complete Cytogenetic Response (CCyR) On Outcome In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Hypomethylating Agents (HMA)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Qiao, Wei
    Strati, Paolo
    Khan, Navira F.
    Cortes, Jorge E.
    Hoehn, Daniela
    Hu, Jianhua
    Obrien, Susan
    Bryan, Jeffrey
    Prescott, Hillary
    DiNardo, Courtney D.
    Daver, Naval
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    BLOOD, 2013, 122 (21)
  • [32] Response to thalidomide in 9 patients with myelodysplastic syndromes: A promising treatment for early or post-chemotherapy in late forms of MDS.
    Dourado, CMC
    Seixas-Silva, JA
    Besa, EC
    BLOOD, 2000, 96 (11) : 260B - 260B
  • [33] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    BLOOD, 2013, 122 (21)
  • [34] Luspatercept Response in ESA-NaiVe/RS plus Patients and RS-Patients with Low-Intermediate Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Germing, Ulrich
    Gotze, Katharina
    Kiewe, Philipp
    Wolff, Thomas
    Mayer, Karin
    Chromik, Joerg
    Radsak, Markus
    Donovan, Eileen
    Wilson, Dawn M.
    Zhang, Xiaosha
    Laadem, Abderrahmane
    Sherman, Matthew L.
    Attie, Kenneth M.
    Giagounidis, Aristoteles
    BLOOD, 2016, 128 (22)
  • [35] Erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa (EPO): A meta-analysis using the International Working Group criteria (IWGc) for MDS response.
    Moyo, V.
    Lefebvre, P.
    Duh, M. S.
    Bourezak, A.
    Yektashenas, B.
    Woodman, R. C.
    Mundle, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 354S - 354S
  • [36] Comparison of erythroid response (ER) rates in myelodysplastic syndromes (MDS) patients treated with different therapeutic strategies using epoetin alfa (EPO).
    Moyo, Victor
    Lefebvre, Patrick
    Bourezak, Ahmed
    Yektashenas, Behin
    Mundle, Suneel
    BLOOD, 2006, 108 (11) : 295B - 295B
  • [37] IMPACT OF MARROW COMPLETE RESPONSE IN THE NATURAL HISTORY OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) TREATED WITH HYPOMETHYLATING AGENTS
    Pierola, A. Alfonso
    Montalban-Bravo, G.
    Takahashi, K.
    Jabbour, E. J.
    Kadia, T.
    Ravandi, F.
    Cortes, J.
    DiNardo, C.
    Daver, N.
    Borthakur, G.
    Pemmaraju, N.
    Konopleva, M.
    Bueso-Ramos, C.
    Pierce, S.
    Kantarjian, H.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2017, 102 : 263 - 264
  • [38] Oral Rigosertib (ON 01910.Na) Treatment Produces A Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses
    Raza, Azra
    Tycko, Benjamin
    Lee, Sangmin
    Galili, Naomi
    Ali, Abdullah
    Eisenberger, Andrew
    Mears, John G.
    Al-Kali, Aref
    Tibes, Raoul
    Spitzer, Gary
    Wilhelm, Francois
    Mukherjee, Siddhartha
    BLOOD, 2013, 122 (21)
  • [39] In vitro antithymocyte globulin (ATG) stimulation of hemopoietic stem cells: Correlation with clinical response in patients with aplastic anemia (AA) and myelodysplastic syndromes (MDS).
    Killick, S
    Marsh, JCW
    Gordon-Smith, EC
    Gibson, FM
    BLOOD, 1998, 92 (10) : 693A - 693A
  • [40] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
12345